Morgan Stanley Reiterates Underweight on Genmab, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has reiterated an 'Underweight' rating on Genmab (NASDAQ:GMAB) and maintained a $33 price target.
July 31, 2023 | 1:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has reiterated an 'Underweight' rating on Genmab, maintaining a $33 price target.
The 'Underweight' rating from Morgan Stanley suggests that the firm believes Genmab's stock is expected to underperform compared to other stocks. This could potentially lead to a decrease in Genmab's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100